# A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

> **NCT07392892** · PHASE2,PHASE3 · RECRUITING · sponsor: **Pfizer** · enrollment: 840 (estimated)

## Conditions studied

- Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma
- Metastatic Gastric Cancer
- Gastroesophageal Junction Cancer
- Esophageal Adenocarcinoma

## Interventions

- **BIOLOGICAL:** PF-08634404
- **DRUG:** Chemotherapy
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT07392892
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-28
- **Primary completion:** 2031-07-22
- **Final completion:** 2032-07-21
- **Target enrollment:** 840 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07392892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07392892, "A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07392892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*